Syndax Annouces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
Syndax Annouces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
March 1, 2011
SYNDAX ANNOUNCES START OF NCI SPONSORED PHASE 2 STUDY OF ENTINOSTAT IN COMBINATION IN TRIPLE NEGATIVE BREAST CANCER